Respiratory β-2-Microglobulin exerts pH dependent antimicrobial activity

Armin Holch**, Richard Bauer**, Lia-Raluca Olari**, Armando A. Rodriguez c,d, Ludger Stärdker c, Nico Preising**, Merve Karacan*, Sebastian Wiese d, Paul Walther e, Yasser B. Ruiz-Blanco f, Elsa Sanchez-Garcia f, Christian Schumann g, Jan Münch a,b,c, and Barbara Spellerberg a

**Institute of Medical Microbiology and Hygiene, University Hospital, Ulm, Germany; *Institute of Molecular Virology, University Hospital, Ulm, Germany; CCore Facility Functional Peptidomics, Ulm University Medical Center, Ulm, Germany; CCore Unit Mass Spectrometry and Proteomics, Ulm University, Ulm, Germany; CCentral Facility for Electron Microscopy, Ulm University Medical Center, Ulm, Germany; CComputational Biochemistry, Center of Medical Biotechnology, University of Duisburg-Essen, Essen, Germany; CPneumology, Thoracic Oncology, Sleep and Respiratory Critical Care Medicine, Clinics Kempten-Allgäu, Kempten and Immenstadt, Germany

ABSTRACT

The respiratory tract is a major entry site for microbial pathogens. To combat bacterial infections, the immune system has various defense mechanisms at its disposal, including antimicrobial peptides (AMPs). To search for novel AMPs from the respiratory tract, a peptide library from human broncho-alveolar-lavage (BAL) fluid was screened for antimicrobial activity by radial diffusion assays allowing the efficient detection of antibacterial activity within a small sample size. After repeated testing-cycles and subsequent purification, we identified β-2-microglobulin (B2M) in antibacterially active fractions. B2M belongs to the MHC-1 receptor complex present at the surface of nucleated cells. It is known to inhibit the growth of Listeria monocytogenes and Escherichia coli and to facilitate phagocytosis of Staphylococcus aureus. Using commercially available B2M we confirmed a dose-dependent inhibition of Pseudomonas aeruginosa and L. monocytogenes. To characterize AMP activity within the B2M sequence, peptide fragments of the molecule were tested for antimicrobial activity. Activity could be localized to the C-terminal part of B2M. Investigating pH dependency of the antimicrobial activity of B2M demonstrated an increased activity at pH values of 5.5 and below, a hallmark of infection and inflammation. Sytox green uptake into bacterial cells following the exposure to B2M was determined and revealed a pH-dependent loss of bacterial membrane integrity. TEM analysis showed areas of disrupted bacterial membranes in L. monocytogenes incubated with B2M and high amounts of lysed bacterial cells. In conclusion, B2M as part of a ubiquitous cell surface complex may represent a potent antimicrobial agent by interfering with bacterial membrane integrity.

Introduction

The respiratory tract represents one of the major entry sites for microbial pathogens. While ventilation and alveolar gas exchange ensures a proper oxygen supply of the human body it also exposes the mucosal membranes of the upper and lower respiratory tract to infectious agents and renders them into a predilection site for infections. Various microbial pathogens affect the lower respiratory tract causing serious and often life-threatening pulmonary infections. Lower respiratory tract infections (LRTI) have major health implications and represented in 2015 the fifth leading cause of death globally and the leading cause of death in children younger than 5 years [1]. To prevent these types of infection the respiratory tract is equipped with various defense mechanisms. Secreted mucus acts as protective layer that binds inhaled noxious substances and pathogens. Kinocilia, of the respiratory epithelium, create a tracheo-oral flow of mucus to remove bacteria and other substances from the airways, a mechanism known as mucociliary clearance. Additionally, the innate immune system offers protection against respiratory infections through antimicrobial peptides (AMPs). These peptides comprise a large group of anti-infective agents with anti-bacterial [2], anti-viral [3] or anti-fungal [4] activity. Further functions may include immunomodulatory properties. Most AMPs are small cationic peptides (10–50 amino acids) with amphiphilic properties, facilitating the insertion of AMPs into the lipid bilayer of bacterial cell membranes. The well-known AMPs LL37, belonging to the cathelicidin family and

CONTACT Jan Münch, barbara.spellerberg@uniklinik-ulm.de, Institute of Molecular Virology, University Hospital Ulm, Ulm 89081, Germany; Barbara Spellerberg, barbara.spellerberg@uniklinik-ulm.de, Institute Medical Microbiology and Hygiene, University Hospital Ulm, Albert-Einstein-Allee 11, Ulm 89081, Germany

*These authors contributed equally to this work

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
human beta-defensins have previously been shown to be present in the respiratory tract [5,6].

Due to its frequent exposure to infective pathogens, the respiratory tract is a promising region for the search of novel AMPs which can effectively be isolated from complex peptide libraries [7,8]. Screening and subsequent separation of antibacterial active fractions enabled the identification of endogenous AMPs from various biological materials of human origin. Peptides modulating viral infections were identified from libraries derived from human hemofiltrate [9–12] or human semen [13,14] using cell-based viral infection assays. Human plasma was the source for the identification of human beta-defensin 1 [15] and human milk for the identification of the antibacterial peptide Casein k(63–117) [16]. Additionally, β-2 Microglobulin (B2M) was purified from amniotic fluid in a screen for antibacterial peptides [17].

B2M is part of the MHC-I receptor that is present at the surface of nearly all nucleated cells [18]. The processed peptide contains 99 amino acids with a molecular weight of 11.7 kDa and is slightly anionic with a net charge of −2 [19]. In the clinical context, B2M can be used as a biological marker for the renal function. In addition, increased serum levels of B2M are linked to inflammatory disease [20] and HIV-1 infections [21]. Due to its ability to form amyloid fibrils B2M is responsible for the development of hemodialysis related amyloidosis [22,23]. A physiological function of B2M in the context of host defense is indicated by its antibacterial effect. B2M shows activity against L. monocytogenes, Staphylococcus aureus, Proteus vulgaris, and Escherichia coli [17]. Furthermore, the peptide is the precursor of a fragment secreted from human respiratory epithelial cells which serves as chemotactic agent for THP-1 monocytes, thus enhancing phagocytosis of Staphylococcus aureus [24]. A reported dose-dependent upregulation of B2M mRNA and secretion of B2M upon stimulation of amniotic cells with bacterial lipopolysaccharide further supports the hypothesis of the antibacterial peptide function [17].

As the exploration of the human peptidome proved to be a powerful tool for the identification of novel AMPs, we used this method to search for AMPs in the respiratory tract. Screening a peptide library derived from 20 l of pooled broncho-alveolar-lavage (BAL) fluid, resulted in the identification of a fraction with antimicrobial activity against Gram-positive and Gram-negative bacterial pathogens containing B2M. An increased antibacterial activity of B2M was observed at acidic pH values that are a hallmark for infection and inflammation [25]. Furthermore Sytox green uptake and electron microscopic investigations pointed toward a membrane disruptive action of the peptide. By prediction-based fragmentation of B2M and subsequent determination of bacterial growth inhibition we could locate its antimicrobial activity to the C-terminal part of the peptide. B2M may thus play an important role in innate immunity as an antimicrobial peptide.

**Materials and methods**

**Preparation of BAL peptide library**

Clinical samples of BAL comprising a total of 20 l were collected and immediately frozen for further processing. Peptide/protein extraction was done by acidification with acetic acid to pH 3, followed by centrifugation at 4,200 rpm, and filtration (0.45 μm) of the supernatant. Further, the filtered BAL was subjected to ultrafiltration (cutoff: 30 kDa) yielding 22 l of a sample enriched in peptides and small proteins. Chromatographic fractionation of the ultrafiltrate sample was performed by using a reversed-phase (PS/DVB) HPLC column Sepax Poly RP300 (Sepax Technologies, Newark DE, USA 260,300–30,025) of dimensions 3 × 25 cm, at a flow rate of 55 ml/min with the gradient program (min/%B): 0/5 5/5 20/25 35/50 50/75 55/0, being A, 0.1% TFA (Merck, 1,082,621,000) in ultrapure water, and B, 0.1% TFA in acetonitrile (J.T. Baker, JT9012-3). Seventy-three reversed-phase chromatographic fractions of 50 ml were collected to constitute the BAL peptide bank, from which 1 mL- aliquots were lyophilized and used for antimicrobial activity testing. For further purification of active fractions, a reversed-phase C18 HPLC column (1 × 25 cm) (Phenomenex, 00 G-4601-N0) was used at a flow rate of 1.8 ml/min with the gradient program (min/%B): 0/5 60/60 70/80.

This study was approved by the Ethics Committee of Ulm University (file number 324/12). BAL was obtained from patients at the Section Pneumology, Internal Medicine II, University Hospital Ulm, Germany. All subjects gave written informed consent in accordance with the Declaration of Helsinki.

**Mass spectrometry analysis**

For intact mass measurement, the sample (either unmodified or carbamidomethylated and digested) was analyzed without any modification. Subsequently, MS/MS measurement was done also after carbamidomethylation and digestion with trypsin for sequencing.
of the proteolytic fragments. The sample was reduced with 5 mM DTT for 20 min at RT, carboxymethylated with 50 mM iodoacetamide for 20 min at 37°C, and digested with trypsin (Thermo Fisher Scientific, 900,589), at a 1:50 ratio (enzyme:protein) for 16 h at 37°C.

A 15 μL-aliquot of the sample (either unmodified or carboxymethylated and digested) was measured using an LTQ Orbitrap Velos Pro system (Thermo Fisher Scientific) online coupled to an U3000 RSLCnano (Thermo Fisher Scientific) uPLC as described previously [26] with the following modifications: For separation, a binary gradient consisting of solvent A, 0.1% formic acid (Merck, 5,438,040,250) in LC-MS grade water (Merck, 1,153,334,000), and solvent B, 0.1% formic acid in 86% acetonitrile (Merck, 1,000,304,000) was employed. After loading onto the precolumn, the sample was concentrated and washed in 5% B for 5 min. In the first elution step, the percentage of B was raised from 5 to 15% in 5 min, followed by an increase from 15 to 40% B in 30 min. The column was washed with 95% B for 4 min and re-equilibrated for subsequent analysis with 5% B for 19 min.

For visualization in XCalibur Qual Browser (Thermo Fisher Scientific), the theoretical B2M mass spectrum with respect to the observed charge states was predicted from its sequence (UniProtKB – P61769) and compared to the experimental mass spectrum.

Database searches were performed using PEAKs X+, http://www.bioinfor.com/peaks-studio [27]. For peptide identification, MS/MS spectra were correlated with the UniProt human reference proteome set, www.uniprot.org. Carboxymethylated cysteine was considered as a fixed modification along with oxidation (M) as a variable modification. False discovery rates were set on the peptide level to 1%. Theoretical average molecular masses were calculated with ProtParam, https://web.expasy.org/protparam/.

Virtual screening and design of modified B2M fragments

To localize the region in B2M responsible for its antibacterial activity, the amino acid sequence of B2M was subjected to a massive virtual screening of all possible fragments with a sequence length between 10 and 30 residues (2078 peptides in total). Our in-house machine-learning-based predictor, ABP-Finder (https://protcalc.zmb.uni-duesseldorf.de/ABP-Finder/index.php) [28], was used to first identify putative antibacterial peptides (ABP), and to predict whether the bacterial targets for each of these ABP belong to the classes Gram-positive, Gram-negative, or to both types of the Gram staining assay. ABP-Finder was used to score the 2078 peptides derived from B2M. Those fragments with a probability score larger than 0.7 were extracted, resulting in 282 peptides. Subsequently, the CD-Hit program [29,30] was used to cluster the annotated peptides using a sequence identity threshold of 70% related to the peptide in the center of the cluster, which led to 19 clusters. Five clusters were discarded because of their low population (see Table S1 in Supplementary Information). From each of the remaining 14 clusters, the peptide with maximum ABP-Finder score was selected. Among these 14 candidates, four peptides were not further considered because their sequences fully overlapped with part of the sequences of other candidates. Thus, the sequence identity screening resulted in 10 representative peptides from the high-scored fragments predicted using ABP-Finder (Table S1). Peptides were then selected for experimental evaluation, based on their scores and the fact that these peptides sampled distinct ranges in the sequence of the B2M peptide (Fig. 7 and Table S1).

Modified fragments of the C-terminal part of B2M containing single amino acid exchanges were generated by AMPA, http://tcoffee.org/cat/apps/ampa/do [31,32], CAMPR3, http://www.camp.bicnirrh.res.in/prediction.php [33] using the Rational Design of Antimicrobial Peptides tool, and then evaluated by CAMPR3-Predict Antimicrobial Peptide tool, Antibp2, http://crdd.osdd.net/raghava/antibp2/ [34], ClassAMP, http://www.bicnirrh.res.in/classamp/predict.php [35] Peptide AMP Scanner, https://www.dveltri.as.jp/v2/ascan.html [36] and iAMPpred, http://cabgrid.res.in:8080/amppred/server.php [37].

Screening the BAL library and purified peptides for antibacterial activity

To identify library fractions and purified peptides with antibacterial activity a radial diffusion assay was carried out. Bacteria were cultured in liquid THY broth (Todd-Hewitt Broth [Oxoid, CM0189B] supplemented with 0.5% yeast extract [BD, Miami, USA, 212,750]) at 37°C overnight in a 5% CO2 atmosphere, pelleted by centrifugation and washed in 10 mM sodium phosphate buffer. Following resuspension in 10 mM sodium phosphate buffer optical density was determined spectrophotometrically at 600 nm (OD600nm). Bacterial density was adjusted to seed 2 × 107 bacteria into a petri dish in 1% agarose dissolved in 10 mM sodium phosphate buffer. Plates were allowed to cool for 30 min at 4°C before several 2–3 mm holes were placed into the 1% agarose. Freeze-dried fractions of the BAL library pool were reconstituted in 200 µl of ddH2O with 10 µl being used for the initial screen. Alternatively, peptides adjusted to the desired concentration in 10 µl of ddH2O were filled into the agar-holes. Following incubation at
37°C in ambient air for 3 h plates were overlaid with 10 ml of a 1% agarose solution containing 3% tryptic soy broth (TSB) dissolved in 10 mM phosphate buffer. Inhibition zones in cm were determined following 16–18 h incubation time at 37°C in a 5% CO₂ atmosphere.

**Survival assay**

*L. monocytogenes* cells (ATCC BAA-679/EGD-e) were grown in THY broth at 37°C in a 5% CO₂ atmosphere overnight. 1 ml of the culture adjusted to an OD₆₀₀nm of 0.1 was centrifuged and the bacterial pellet was resuspended in 1 ml of assay medium (20% TSB dissolved in 20 mM NaPO₄ adjusted to different pH values). 90 µl of the bacterial suspension was mixed with 10 µl of the desired concentration of B2M (Lee Biosolutions, St. Louis, Missouri, 126–12-10) or with 10 µl of ddH₂O (negative control) followed by incubation at 37°C. Samples were taken at the indicated time points, dilutions were prepared and plated on Sheep blood agar plates (TSA+SB, Oxoid, Basingstoke, UK, PB5012A). Colony Forming Units (CFU) were quantified after overnight incubation of the agar plates at 37°C in a 5% atmosphere. Bacterial survival was calculated in comparison to the CFU present at the beginning of the experiment (t = 0 min) and normalized to the mock-treated bacterial sample grown in the corresponding assay medium.

**Sytox green membrane permeabilization**

Two different readouts (fluorescence plate reader and flow cytometer) were used to measure Sytox green (Invitrogen, Thermo Fisher Scientific, Dreieich, Germany S7020) uptake into bacterial cells. For samples analyzed by the flow cytometer, an equivalent of 100 µl of a *L. monocytogenes* (ATCC BAA-679/EGD-e) culture grown to an OD₆₀₀nm of 0.1 were harvested by centrifugation and resuspended in 20% TSB dissolved in 20 mM NaPO₄ adjusted to three different pH values (pH 7, pH 5.5, pH 4.5). The samples were treated with B2M at a concentration of 1 mg/ml or were mock-treated with ddH₂O. After incubation at 37°C for 1 h, the cells were pelleted and resuspended in 20% TSB NaPO₄ adjusted to pH 7, pH 5.5, and pH 4.5 containing 0.02 µM Sytox green stain. Quantification was done by FACS analysis. Bacteria treated with 70% isopropanol served as positive control, mock treated cells (ddH₂O) served as negative control. The percentage of Sytox positive cells is depicted by normalizing the analyzed samples to the positive control. *L. monocytogenes* cells analyzed by fluorescence plate reader were grown till an OD₆₀₀nm of 0.1 was obtained. Bacterial cells were centrifuged and the pellet was resuspended in one volume of 20% TSB NaPO₄ adjusted to pH 7, pH 5.5 and pH 4.5 with 0.2 µM Sytox. 90 µl of the bacterial solutions were mixed with 10 µl of B2M at a concentration of 1 mg/ml or 10 µl of H₂O. Bacteria treated with 70% isopropanol for 5 min were used as positive control. The fluorescence intensity was measured with a Tecan infinite M plate reader using an excitation wavelength of 488 nm. Measurements were performed in three biological replicates with three technical replicates per sample.

**Transmission electron microscopy (TEM)**

*L. monocytogenes* cells, grown to mid-exponential phase, were harvested by centrifugation and resuspended in 20% TSB dissolved in 20 mM NaPO₄ (pH 4.5). Following treatment of 5 × 10⁹ cells with 1 mg/ml B2M for 15 min at 37°C cells were pelleted by centrifugation and fixed with 2.5% glutaraldehyde containing 1% sucrose in phosphate buffer (pH 7.3). Samples were washed 5 times with phosphate buffer and postfixed in 2% aqueous osmium tetroxide. After dehydrating the samples in a graded series of 1-propanol, they were blockstained in 1% uranyl acetate and embedded in Epon. Sections were collected on copper grids, contrasted with 0.3% lead citrate for 1 min and imaged in a Zeiss TEM 109 or in a Jeol TEM 1400.

**Thioflavin T (ThT) measurements**

To monitor the presence of amyloid fibrils, a 2.5 mM stock solution of ThT (Sigma-Aldrich, Schnelldorf, Germany, T3516) in PBS was prepared and sterile filtered. 1 µl of this solution was added to 15 µl of the peptide sample (1 mg/ml), then the sample was filled up to 100 µl using 84 µl of PBS and incubated for 10 minutes in the dark, at room temperature. Of each preparation, 50 µl were transferred to one well of a Corning® 96 well black polystyrene microplate (Sigma-Aldrich, CLS3603). Fluorescence intensity scans were performed at an excitation wavelength of 450 nm and an emission at 482 nm, using a Synergy H1 hybrid multi-mode reader (Biotek, Bad Friedrichshall, Germany). All values represent fluorescence intensity derived from duplicates minus background activity derived from possible background fluorescence. Duplicates were expressed as mean ± standard error derived from two independent experiments.

**Antimicrobial activity of fibrils**

To determine if fibrils of B2M possess antimicrobial activity, a radial diffusion assay was performed. Fibrils were generated by incubation of B2M of 1 mg/ml in 150 µl of 20% TSB NaPO₄ adjusted to pH 7 and pH 4.5 for 30 min at 37°C. After centrifugation, the supernatant was collected
and the pelleted fibrils were dissolved in 150 μl of the corresponding buffer. The supernatant and the fibril solutions were then assayed in a radial diffusion assay as described above.

Results

Antimicrobial screening of BAL peptide library

Chromatographic fractionation of the pooled BAL samples yielded 73 fractions that were subsequently screened for inhibiting bacterial growth. For evaluating the antimicrobial activity of the BAL peptide library, a radial diffusion assay that can be carried out with microliter amounts of the fractions of the library was used (Figure 1(a)). Screening was performed with the following bacterial species: Bacillus subtilis, Pseudomonas aeruginosa, Staphylococcus aureus MRSA, and Klebsiella pneumonia. In the initial screen several neighboring fractions of the library showed a strong antimicrobial activity against B. subtilis and P. aeruginosa, which were therefore selected for further testing (Figure 1(b)). Fraction 36 was chosen for further analysis due to its location in the middle of the observed peak and based on the fact that it demonstrated the highest antibacterial activity against P. aeruginosa, which causes infections in humans. The active fractions were subjected to reversed-phase C18 HPLC and the resulting fractions were evaluated for their antimicrobial activity (Figure 1(b), Fig. S1). A high-intensity chromatographic fraction (Nr. 57) displaying inhibitory activity was separated and analyzed by mass spectrometry. The deconvoluted molecular mass from the dominant multiply-charged ion cluster (Figure 2(a)) was 11,729.41 Da. Subsequent MS/MS analysis of proteolytic fragments generated by tryptic digest of this fraction indicated a 93% coverage of the B2M mature sequence (UniProtKB – P61769, Figure 2 C + D). In addition, the experimental multiply-charged signals closely matched the theoretical ones (Figure 2(b)) as well as the expected molecular mass of 11,729.15 Da, calculated from the mature sequence (21–119) of B2M while considering the formation of a single disulfide bridge. Furthermore, this MS data for B2M is consistent with the MS data from a comprehensive study on human hemofiltrate peptides [38], where mature B2M was identified among others. Taken together, MS data of fraction 57 indicate the presence of mature B2M (21–119).

Antibacterial activity of B2M

Following the isolation of B2M from the peptide library, purified B2M from a commercial supplier was obtained to investigate its antibacterial activity and thus to substantiate our hypothesis that the antimicrobial effect of the purified peptide library fractions was connected to B2M. For P. aeruginosa (ATCC 27853) and Bacillus subtilis, a clear dose-dependent growth inhibition could be observed upon exposure to different amounts of B2M (Figure 3(a)). Since a previous publications described an antimicrobial effect of B2M on

Figure 1. Identification of antimicrobial active BAL fractions. A: Illustration of the screening procedure consisting of repeated rounds of peptide separation via chromatography and testing of peptide fractions via radial diffusion assays. B: The BAL library was tested in a radial diffusion assay against B. subtilis (a Gram-positive species) and P. aeruginosa (a Gram-negative species). Peptide fractions 32 to 40 were able to inhibit the growth of both bacteria. The testing of the second peptide library generated from fraction 36 against B. subtilis led to three remaining active peptide fractions 56 to 58. Lung: Design created by kjargeter – www.freepik.com.
L. monocytogenes [17] the strain ATCC BAA-679/EGD-e was included in our analysis. We confirmed the direct antimicrobial activity of B2M against this strain and show a dose-dependent growth inhibition up to a concentration of 7.5 mg/l (Figure 3(b)).

**pH-dependent antimicrobial effect**

B2M is an amyloidogenic protein known to form fibrils under specific conditions [39]. To investigate, if the antimicrobial effect of B2M is exerted by fibrils or monomers of B2M, thioflavin T measurements of the B2M working solutions used in the assays were carried out and compared to the formation of artificial EF-C fibrils [40] as a control. This analysis revealed (Figure 4(a)) that the B2M solution that was used in our radial diffusion assays, as well as in survival assays is present in its non-aggregated form at pH 7 and shows fibril formation at pH 4.5. After 30 min at pH 4.5 fibrils of B2M could be detected in the solutions that were used for the quantification of antimicrobial activity against L. monocytogenes and P. aeruginosa. Since we observed fibril formation of B2M at low pH values, bacterial growth inhibition through B2M was also studied under different pH conditions. These investigations were carried out with L. monocytogenes and showed a strong pH dependency of the observed antimicrobial activity. In the radial diffusion assays no antimicrobial activity could be detected at pH values of 6 and above, while inhibition zones exceeding 1 cm in diameter were easily visible at pH 4.5 (Figure 4(b)). Similar results were obtained in survival assays, were after 2 hours only about 10% of bacteria were still viable at pH 4.5 and 5.5, whereas identical samples incubated with B2M at pH 7 showed a 90% survival rate (Figure 4(c)). To test if fibrils are involved in the antimicrobial activity of
B2M, we assayed the activity of dissolved fibrils in a radial diffusion assay against *L. monocytogenes* (Table 1). Although a visible pellet of mature B2M fibrils could be obtained by incubation of B2M in assay buffer of pH 4.5, no antimicrobial activity of the fibrils present in the pellet could be detected. Only the supernatant of the B2M solution containing monomers, oligomers, and possibly small fragmented fibrils resulted in a visible zone of inhibition.

**Membrane damage by B2M**

To measure membrane integrity upon exposure of *L. monocytogenes* to B2M, Sytox green uptake into bacterial cells was determined. Following the treatment of *L. monocytogenes* with 1 mg/ml of B2M for up to 1 h an increased fluorescence could be observed in comparison with the respective controls (Fig. S2). Especially under low pH conditions at values of pH 5.5 and 4.5 a considerable proportion of bacterial cells showed a positive fluorescence staining of nucleic acids which was already visible after 15 min of peptide treatment. The results indicate that B2M exerts its antimicrobial properties through a direct membrane damaging effect on *L. monocytogenes*. To further investigate the mechanisms of action of B2M and to visualize the putative membrane damaging effect TEM was carried out. *L. monocytogenes* bacterial cells were treated with 1 mg/ml B2M for 15 min and 2 hours (data not shown) at pH 4.5. Subsequent TEM pictures revealed a substantial reduction of intact bacterial cells following the treatment of *L. monocytogenes* for only 15 min (Figure 5(b)) while controls appeared intact (Figure 5(a)). Taken together these results suggest that B2M damages bacterial cells in a direct interaction with bacterial surface structures resulting in a rapid bacterial lysis.

**Localization and optimization of active B2M fragments**

To further examine, which part of the B2M molecule is responsible for the observed antimicrobial activity, several smaller peptide fragments spanning the entire protein of B2M were generated (Figure 6(a)) based on the virtual screening analysis of B2M for AMPs (Table S1). These

![Figure 3. Antibacterial activity of purified B2M. The dose-dependent antibacterial activity of B2M was tested in a radial diffusion assay against the screening strains *B. subtilis* and *P. aeruginosa* (a), and against *L. monocytogenes* (b). The mean value and standard deviation for three independent experiments is depicted.](image-url)
peptides, were then tested for antimicrobial activity against *P. aeruginosa* at 1 mg/ml. Results of these assays could locate the antimicrobial activity of B2M to a C-terminal fragment of 18 amino acids (B2M_99-116, ACRVNHTLSQPKIVKWD). In an effort to optimize the antibacterial effect of this fragment several modified versions of the peptide were synthesized. A shorter variant (B2M 101–115, RVNVHVTLSQPKIVKWD) was generated by AMPA, an automated webtool, allowing the detection of peptide fragments with putative AMP function in larger proteins [32]. The fragment B2M 101–115 covers most amino acid residues of the entire B2M, which are predicted to exert AMP activity by AMPA. Then, several derivatives (Figure 6(b)) of this fragment were generated by CAMPR3, an online database which contains a sequence optimization algorithm for the rational design of AMPs [33]. The resulting derivatives were evaluated by the programs CAMPR3, antiBP2, ClassAMP, Antimicrobial Peptide Scanner v.r.2 and iAMPpred to confirm their intended AMP activity. The

**Table 1.** Radial diffusion assay of B2M fibril formulations. B2M (1 mg/ml) was incubated for 30 min at 37°C in 150 µl of assay buffer of pH 4.5 or pH 7 allowing for fibril formation. After centrifugation, the supernatant was collected and the resulting fibril pellet was dissolved in 150 µl of assay buffer of pH 4.5 or pH 7. Depicted are the mean ± standard deviation of the zone of inhibition [cm] in a radial diffusion assay against *L. monocytogenes*.

| pH 4.5 | pH 7 |
|--------|------|
| **Undiluted** | | |
| supernatant | fibrils | supernatant | fibrils* |
| 1.03 ± 0.05 | 0 | 0.27 ± 0.05 | 0 |
| 1.2 | 0.90 ± 0.00 | 0 | 0 |
| 1.4 | 0.83 ± 0.05 | 0 | 0 |
| 1.6 | 0.63 ± 0.05 | 0 | 0 |
| 1:16 | 0.43 ± 0.05 | 0 | 0 |
| B2M 1 mg/ml | 1.33 ± 0.05 | | |
| B2M 125 µg/ml | 1.03 ± 0.05 | | |

* no visible fibril pellet was obtained after centrifugation

**Figure 4.** pH-dependent antibacterial activity of purified B2M against *L. monocytogenes*. **A:** Amyloidogenic potential of B2M at low pH conditions. The presence of amyloid fibrils was monitored by ThT staining. B2M was either subjected directly to ThT measurement or was incubated at 37°C for 30 min in buffer with the indicated pH. EF-C fibrils served as positive control (pos control). The mean value and standard deviation for two independent experiments is depicted. **B:** Antibacterial activity of B2M was tested in radial diffusion assays using pH modified agarose solutions (4.5 to 7). Antibacterial activity of B2M in radial diffusion assays could only be observed at pH values lower than 6. **C:** The pH-dependent effect of B2M (1 mg/ml) against *L. monocytogenes* in a survival assay. Peptide and mock-treated bacteria were incubated at pH values 7, 5.5 and 4.5 for 30, 60 and 120 min. Quantification of living bacteria was performed by CFU determination and the values are expressed as % survival compared to mock-treated samples. The mean value ± standard deviation is depicted for three independent experiments.
derivatives D1-D7 (Figure 6(b)) carry up to three amino acid residues replacements at positions 1, 6 and 10, respectively, which were subsequently tested against *P. aeruginosa*. Among these derivatives, the fragments D6 (GVNHVLSQIKIVKW) and D7 (GVNHVKL5QIKIVKW) showed the most convincing enhancement of antimicrobial activity (Figure 6(c)). Compared to the activity of the modified fragment D7 at 25 µg/ml, 2–4 times the amount of the unmodified 15 residues long fragment B2M 101–115 (50–100 µg/ml) were needed to achieve similar inhibition zones.

**Discussion**

Due to a close and constant exposure to the surrounding environment, the respiratory tract represents a major entry portal for microbial pathogens, which may then cause subsequent pulmonary infections. To prevent...
frequent infections respiratory secretions abundantly contain antimicrobial substances. Already 100 years ago Alexander Fleming studied nasal secretions for antimicrobial activity, which led to the discovery of lysozyme [41]. To explore innate respiratory defense mechanisms we screened a human peptide library originating from bronchoalveolar lavage material for antimicrobial peptides, a screen which led to the identification of B2M in one of the fractions with high antibacterial activity (Figure 1(b)) against *P. aeruginosa* and *B. subtilis*. Specific antimicrobial activity of B2M against *P. aeruginosa*, *B. subtilis*, and *L. monocytogenes* could be confirmed with commercially available B2M. For *L. monocytogenes* a dose-dependent antibacterial activity could still be detected at a concentration as low as 7.5 mg/l (Figure 3(b)). Our data demonstrate a direct antimicrobial effect of B2M comprising Gram-negative as well as Gram-positive bacterial pathogens.

B2M is a small amyloidogenic human protein of 99 amino acids with a molecular weight of 11.7 kDa. It is found in varying amounts throughout different organs and tissues of the human body, since it is part of the MHC class I complex present on all nucleated cells. It is associated with the MHC class I molecule but not covalently bound to it. B2M is essential for antigen binding and known to play a role in maintaining the correct structure of the MHC class I complex [42]. In BAL fluid of healthy adults, it reaches concentrations of 0.08 mg/l with higher concentrations observed in children [43], while serum concentrations of B2M range between 1 and 3 mg/l [20]. A large fragment of B2M has also been detected in the culture supernatant of respiratory epithelial cells upon stimulation with IL-1β [24]. It was shown to generate aggregates of *S. aureus*, facilitating the phagocytosis of clusters of bacteria by THP-1 cells. Among various other antimicrobial peptides, B2M has previously been detected in human airway fluid demonstrating antimicrobial activity against *P. aeruginosa* and *L. monocytogenes* [44]. In animal models B2M knock out mice showed enhanced susceptibility toward *L. monocytogenes* [45] as well as *K. pneumoniae* infections [46]. However, in animal experiments, it is difficult to decide, which part of the antimicrobial effect may be due to a direct antimicrobial activity of B2M and which part is due to the loss of immunological functions that accompanies a B2M knockout.

Concerning its amyloidogenic nature under pathological conditions, B2M is the main cause of dialysis-associated amyloidosis [47], a property that is specific for human B2M. Human B2M has the ability to form fibrils, in contrast to mouse B2M, which therefore does not represent an amyloid [39]. The antimicrobial properties of amyloids represent a major research focus of recent years. Apart from amyloid beta, which causes Alzheimer’s disease and has been shown to exert antimicrobial properties several years ago [48,49], other amyloid-forming polypeptides such as protegrin-1 serum amyloid A, and temporins, have been demonstrated to inhibit bacterial growth [50]. Additional antimicrobial properties of amyloid β and protegrin include antiviral and antifungal activities. B2M has previously been associated with antimicrobial activity against *L. monocytogenes* [17], however a detailed analysis of the antimicrobial mechanism and which part of the molecule is responsible for its antibacterial activity has not been performed. The analysis of B2M preparations that were used in antimicrobial studies by thioflavin T assays did not show any mature fibrils at pH 7 but fibril formation occurred at pH 4.5, where a strong antimicrobial effect was observed (Figure 4). To investigate if the antibacterial effect may be linked to the fibrillar form of human B2M, which occurs at low pH [39], the antibacterial activity of B2M fibrils and monomers was studied. Interestingly, the amino acid sequence NHVTLSQ, which is responsible for the amyloid formation of B2M is located in the C-terminal fragment of B2M that showed antimicrobial activity in the fragment analysis. However, only the supernatant of a B2M fibril preparation containing the monomeric and oligomeric form of B2M and possibly smaller fibril fragments demonstrated antibacterial activity in radial diffusion assays. Since the pellet of this preparation, which contains mature B2M fibrils, does not demonstrate antimicrobial activity, these fibrils cannot be responsible for the inhibition zones that are produced by B2M in radial diffusion assays (Figures 3, and 4). A previous publication showed a strong pH-dependent membrane damage of B2M fibril fragments in assays with artificial anionic phospholipid membranes [51]. These results are consistent with our observation under the assumption that small fragmented B2M fibrils were present in the supernatant of our fibril preparation.

Antimicrobial peptides may kill bacteria through various mechanisms. One of the most common mechanisms relies on the disruption of bacterial membrane integrity through the interaction of cationic AMPs with the anionic bacterial plasma membrane present in Gram-negative as well as Gram-positive bacterial cells [52]. To explore the effects of B2M on bacterial cell integrity, Sytox green experiments were performed showing a significant bacterial membrane disruption in a pH-dependent manner as early as 15 min after B2M exposure (Fig. S2). Electron microscopy analysis of bacteria incubated for only 15 minutes with B2M supported the hypothesis of a lytic action as the relevant antimicrobial mechanisms. In addition to a marked reduction of the number of bacteria present in
samples treated with B2M, damaged bacterial cells devoid of intracellular content could be clearly detected in the TEM pictures.

The activity of many AMPs is pH-dependent. Quite a number of well-characterized antimicrobial peptides including AMPs like the cathelicidin LL-37, lactoferrin, hepcidin, histatins, dermcidins and the hemoglobin fragment HBB demonstrate a low pH optimum [53,54]. Since acidic pH-values are present at sites of infection, the skin, the vagina, in sweat and within the lysosomal compartment of phagocytic cells, an increased antimicrobial activity under these conditions is advantageous for the host. B2M as an ubiquitous human cell surface molecule is expected to be present in all of this different host niches and has been demonstrated, for example, in sweat [55]. The protonation of histidine, aspartic acid, and glutamic acid residues has been suggested as a relevant mechanisms to explain the altered activity of AMPs at low pH [53]. In our case the protonation of amino acids may have been facilitated by the extraction of peptides from the BAL fluid under acidic conditions. Furthermore, the net charge of B2M changes from –2 at neutral pH to a net positive charge of about 4–5 at pH 5 (http://protcalc.sourceforge.net/). These changes may facilitate the insertion of B2M into anionic bacterial membranes or the formation of the responsible bioactive structure. Our results clearly show a pH-dependent antimicrobial activity for B2M, which is supported by an increase in membrane damage at low pH.

In summary, we were able to isolate B2M as an antimicrobial peptide from the respiratory tract. We could show a pH-dependent antimicrobial activity that can be located to the C-terminus of the molecule. B2M causes a rapid lysis of bacterial cells which appears to be attributable to an interference of B2M with bacterial cell membrane integrity.

Acknowledgments
A.H., R. B., L. O., L.S., A.R., N. P., M. K., S. W., P.W., Y. R., E. S., J.M., and B.S thank the German Research Foundation (DFG) for funding within the CRC1279. E.S-G. acknowledges the Boehringer Ingelheim Foundation (Plus-3 grant) and the DFG under Germany’s Excellence Strategy – EXC 2033 – 390677874 – RESOLV.

Disclosure statement
No potential conflict of interest was reported by the authors.

Funding
This work was supported by the Deutsche Forschungsgemeinschaft [CRC1279]. A.H., R. B., L. O., L.S., A.R., N. P., M. K., S. W., P.W., Y. R., E. S., J.M., and B.S thank the German Research Foundation (DFG) for funding within the CRC1279. E.S-G. acknowledges the Boehringer Ingelheim Foundation (Plus-3 grant) and the DFG under Germany’s Excellence Strategy – EXC 2033 – 390677874 – RESOLV.

References
[1] Collaborators GL. Estimates of the global, regional, and national morbidity, mortality, and aetologies of lower respiratory tract infections in 195 countries: a systematic analysis for the global burden of disease study 2015. Lancet Infect Dis. 2017;17(11):1133–1161.
[2] Brogdon KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol. 2005;3(3):238–250.
[3] Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol. 2006;6(6):447–456.
[4] Aerts AM, Francois IE, Cammue BP, et al. The mode of antifungal action of plant, insect and human defensins. Cell Mol Life Sci. 2008;65(13):2069–2079.
[5] Fahy RJ, Wewers MD. Pulmonary defense and the human cathelicidin hCAP-18/LL-37. Immunol Res. 2005;31(2):75–89.
[6] Bastos P, Trindade F, da Costa J, et al. Human antimicrobial peptides in bodily fluids: current knowledge and therapeutic perspectives in the Postantibiotic Era. Med Res Rev. 2018;38(1):101–146.
[7] Bosso M, Standker L, Kirchhoff F, et al. Exploiting the human peptidome for novel antimicrobial and anticancer agents. Bioorg Med Chem. 2018;26(10):2719–2726.
[8] Munch J, Standker L, Forssmann WG, et al. Discovery of modulators of HIV-1 infection from the human peptidome. Nat Rev Microbiol. 2014;12(10):715–722.
[9] Detheux M, Standker L, Vakili J, et al. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med. 2000;192(10):1501–1508.
[10] Munch J, Standker L, Pohlmann S, et al. Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages. Antimicrob Agents Chemother. 2002;46(4):982–990.
[11] Zirafi O, Kim KA, Standker L, et al. Discovery and characterization of an endogenous CXCR4 antagonist. Cell Rep. 2015;11(5):737–747.

[12] Munch J, Standker L, Adermann K, et al. “Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell. 2007;129(2):263–275.

[13] Munch J, Rucker E, Standker L, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell. 2007;131(6):1059–1071.

[14] Arnold F, Schnell J, Zirafi O, et al. Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection. J Virol. 2012;86(2):1244–1249.

[15] Bensch KW, Raida M, Magert HJ, et al. hBD-1: a novel beta-defensin from human plasma. FEBS Lett. 1995;368(2):331–335.

[16] Liepe C, Zucht HD, Forssmann WG, et al. Purification of novel peptide antibiotics from human milk. J Chromatogr B Biomed Sci Appl. 2001;752(2):369–377.

[17] Kim YJ, Park SC, Lee JK, et al. Novel antibacterial activity of beta(2)-microglobulin in human amniotic fluid. PLoS One. 2012;7(11):e47642.

[18] Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987;329(6139):506–512.

[19] Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 2016;44(D1):D1087–1093.

[20] Walters MT, Stevenson FK, Goswami R, et al. Comparison of serum and synovial fluid concentrations of beta 2-microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis. Ann Rheum Dis. 1989;48(11):905–911.

[21] Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322(3):166–172.

[22] Danesh F, Ho LT. Dialysis-related amyloidosis: history and clinical manifestations. Semin Dial. 2001;14(2):80–85.

[23] Hirakura Y, Kagan BL. Pore formation by beta-2-microglobulin: a mechanism for the pathogenesis of dialysis associated amyloidosis. Amyloid. 2001;8(2):94–100.

[24] Chioj SJ, Wang CC, Tseng YS, et al. A novel role for beta2-microglobulin: a precursor of antibacterial chemokine in respiratory epithelial cells. Sci Rep. 2016;6:31035.

[25] Casimir GJ, Lefeve N, Corazza F, et al. The acid-base balance and gender in inflammation: a mini-review. Front Immunol. 2018;9:475.

[26] Mohr KB, Zirafi O, Hennies M, et al. Sandwich enzyme-linked immunosorbent assay for the quantification of human serum albumin fragment 408–423 in bodily fluids. Anal Biochem. 2015;476:29–35.

[27] Zhang J, Xin L, Shan B, et al. PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification. Mol Cell Proteomics. 2012;11(4):M111 010587.

[28] Romero-Molina S, Ruiz-Blanco YB, Green JR, et al. ProtDCal-Suite: a web server for the numerical codification and functional analysis of proteins. Protein Sci. 2019;28(9):1734–1743.

[29] Li W, Godzik A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics. 2006;22(13):1658–1659.

[30] Fu L, Niu B, Zhu Z, et al. CD-HIT: accelerated for clustering the next-generation sequencing data. Bioinformatics. 2012;28(23):3150–3152.

[31] Torrent M, Nogues VM, Boix E. A theoretical approach to spot active regions in antimicrobial proteins. BMC Bioinformatics. 2009;10:373.

[32] Torrent M, Di Tommaso P, Pulido D, et al. AMPA: an automated web server for prediction of protein anti-microbial regions. Bioinformatics. 2012;28(1):130–131.

[33] Wagh FI, Barai RS, Gurung P, et al. CAMPR3: a database on sequences, structures and signatures of antimicrobial peptides. Nucleic Acids Res. 2016;44(D1):D1094–1097.

[34] Lata S, Mishra NK, Raghava GP. AntiBP2: improved version of antibacterial peptide prediction. BMC Bioinformatics. 2010;11(Suppl 1):S19.

[35] Joseph S, Karnik S, Nilawe P, et al. ClassAMP: a prediction tool for classification of antimicrobial peptides. IEEE/ACM Trans Comput Biol Bioinform. 2012;9(5):1535–1538.

[36] Veltri D, Kamath U, Shehu A. Deep learning improves antimicrobial peptide recognition. Bioinformatics. 2018;34(16):2740–2747.

[37] Meher PK, Sahu TK, Saini V, et al. Predicting antimicrobial peptides with improved accuracy by incorporating the compositional, physico-chemical and structural features into Chou’s general PseAAC. Sci Rep. 2017;7:43262.

[38] Richter R, Schulz-Knappe P, Schrader M, et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B Biomed Sci Appl. 1999;726(1–2):25–35.

[39] Ivanova MI, Sawaya MR, Gingery M, et al. An amyloid-forming segment of beta2-microglobulin suggests a molecular model for the fibril. Proc Natl Acad Sci U S A. 2004;101(29):10584–10589.

[40] Yolamanova M, Meier C, Shaytan AK, et al. Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. Nat Nanotechnol. 2013;8(2):130–136.

[41] Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. Proc R Soc Lond Ser B Biol sci. 1922;93(653):306–317.

[42] Berko D, Carmi Y, Cafri G, et al. Membrane-anchored beta 2-microglobulin stabilizes a highly receptive state of MHC class I molecules. J Immunol. 2005;174(4):2116–2123.

[43] Ratjen F, Kreuzfelder E. Immunoglobulin and beta 2-microglobulin concentrations in bronchoalveolar lavage of children and adults. Lung. 1996;174(6):383–391.

[44] Cole AM, Liao HJ, Stuchlik O, et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol. 2002;169(12):6985–6991.

[45] Roberts AD, Ordway DJ, Orme IM. Listeria monocytogenes infection in beta 2 microglobulin-deficient mice. Infect Immun. 1993;61(3):1113–1116.
[46] Cogen AL, Moore TA. Beta2-microglobulin-dependent bacterial clearance and survival during murine Klebsiella pneumoniae bacteremia. Infect Immun. 2009;77(1):360–366.

[47] Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. Biochem Biophys Res Commun. 1985;129(3):701–706.

[48] Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One. 2010;5(3):e9505.

[49] Brothers HM, Gosztyla ML, Robinson SR. The physiological roles of amyloid-beta peptide hint at new ways to treat Alzheimer’s disease. Front Aging Neurosci. 2018;10:118.

[50] Kagan BL, Jang H, Capone R, et al. Antimicrobial properties of amyloid peptides. Mol Pharm. 2012;9(4):708–717.

[51] Goodchild SC, Sheynis T, Thompson R, et al. Beta2-Microglobulin amyloid fibril-induced membrane disruption is enhanced by endosomal lipids and acidic pH. PLoS One. 2014;9(8):e104492.

[52] Mahlapuu M, Hakansson J, Ringstad L, et al. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6:194.

[53] Malik E, Dennison SR, Harris F, et al. pH dependent antimicrobial peptides and proteins, their mechanisms of action and potential as therapeutic agents. Pharmaceuticals (Basel). 2016;9:4.

[54] Gross R, Bauer R, Kruger F, et al. A placenta derived C-terminal fragment of beta-hemoglobin with combined antibacterial and antiviral activity. Front Microbiol. 2020;11:508.

[55] Park JH, Park GT, Cho IH, et al. An antimicrobial protein, lactoferrin exists in the sweat: proteomic analysis of sweat. Exp Dermatol. 2011;20(4):369–371.